• 1
    Chambers RC. Procoagulant signaling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008; 153 Suppl 1: S36778.
  • 2
    Howell DC, Laurent GJ, Chambers RC. Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem Soc Trans 2002; 30: 2116.
  • 3
    Green D. Coagulation cascade. Hemodial Int 2006; 10 Suppl 2: S24.
  • 4
    Mann KG. Thrombin formation. Chest 2003; 124: 410S.
  • 5
    Ludwicka-Bradley A, Bogatkevich G, Silver RM. Thrombin- mediated cellular dysfunction in pulmonary fibrosis associated with systemic sclerosis (scleroderma). Clin Exp Rheumatol 2004; 22 Suppl 33: S3846.
  • 6
    Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 25864.
  • 7
    Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblast to a myofibroblast phenotype via proteolytically activated receptor-1 and protein kinase C-dependent pathway. J Biol Chem 2001; 276: 4518492.
  • 8
    Bogatkevich GS, Gustilo E, Oates J, Feghali-Bostwick C, Harley RA, Silver RM, et al. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005; 288: L190201.
  • 9
    Ohba T, McDonald JK, Silver RM, Strange C, LeRoy EC, Ludwicka A. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of the platelet-derived growth factor α-receptor. Am J Respir Cell Mol Biol 1994; 10: 40512.
  • 10
    Gray AJ, Bishop JE, Reeves JT, Laurent GJ. Aα and Bβ chains of fibrinogen stimulate proliferation of human fibroblasts. J Cell Sci 1993; 104: 40913.
  • 11
    Bachhuber BG, Sarembock IJ, Gimple LW, Owens GK. α-thrombin induces transforming growth factor-β1 mRNA and protein in cultured vascular smooth muscle cells via a proteolytically activated receptor. J Vasc Res 1997; 34: 418.
  • 12
    Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 2000; 275: 3558491.
  • 13
    Bogatkevich GS, Ludwicka-Bradley A, Paul J. Nietert, Silver RM. Scleroderma lung fibroblasts: contractility and connective tissue growth factor. In GabbianiG, ChaponnierC, DesmouliereA, editors. Myofibroblasts. Georgetown (TX): Landes Bioscience; 2006. p 2531.
  • 14
    Mercer PF, Deng X, Chambers RC. Signaling pathways involved in proteinase-activated receptor1-induced proinflammatory and profibrotic mediator release following lung injury. Ann N Y Acad Sci 2007; 1096: 868.
  • 15
    Ludwicka-Bradley A, Tourkina E, Suzuki S, Tyson E, Bonner M, Fenton JW II, et al. Thrombin upregulates interleukin-8 in lung fibroblasts via cleavage of proteolytically activated receptor-I and protein kinase C-γ activation. Am J Respir Cell Mol Biol 2000; 22: 23543.
  • 16
    Tourkina E, Hoffman S, Fenton JW II, Lipsitz S, Silver RM, Ludwicka-Bradley A. Depletion of protein kinase Cϵ in normal and scleroderma lung fibroblasts has opposite effects on tenascin expression. Arthritis Rheum 2001; 44: 137081.
  • 17
    Chambers RC, Dabbagh K, McAnulty RJ, Gray AJ, Blanc-Brude OP, Laurent GJ. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 1998; 333: 1217.
  • 18
    Armstrong MT, Fenton JW II, Andersen TT, Armstrong PB. Thrombin stimulation of matrix fibronectin. J Cell Physiol 1996; 166: 11220.
  • 19
    Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159: 138395.
  • 20
    Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005; 166: 135365.
  • 21
    Sorbera LA, Bozzo J, Castaner J. Dabigatran/dabigatran etexilate. Drugs Future 2005; 30: 87785.
  • 22
    Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009; 60: 345564.
  • 23
    Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 24582.
  • 24
    Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 15562.
  • 25
    Silver RM, Metcalf JF, Stanley JH, LeRoy EC. Interstitial lung disease in scleroderma: analysis by bronchoalveolar lavage. Arthritis Rheum 1984; 27: 125462.
  • 26
    Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 46770.
  • 27
    Laurent GJ, Cockerill P, McAnulty RJ, Hasting JR. A simplified method for quantitation of the relative amounts of type I and type III collagen in small tissue samples. Anal Biochem 1981; 113: 30112.
  • 28
    Troconiz IF, Tillmann C, Liesenfeld KH, Schaefer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective hip replacement surgery. J Clin Pharmacol 2007; 47: 37182.
  • 29
    Palm M, Frankenberg L, Johansson M, Jalkesten E. Evaluation of coagulation tests in mouse plasma. Comp Haematol Int 1997; 7: 2436.
  • 30
    Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 36282.
  • 31
    Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, et al. Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995; 10: 187683.
  • 32
    Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009; 2: 10321.
  • 33
    Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138: 5406.
  • 34
    Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 25573.
  • 35
    Maeda A, Ishioka S, Taooka Y, Hiyama K, Yamakido M. Expression of transforming growth factor-β1 and tumour necrosis factor-α in bronchoalveolar lavage cells in murine pulmonary fibrosis after intraperitoneal administration of bleomycin. Respirology 1999; 4: 35963.
  • 36
    Tani K, Ogushi F, Takahashi H, Kawano T, Endo T, Sone S. Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats—significance in bleomycin-induced pulmonary fibrosis. J Med Invest 1997; 44: 5965.
  • 37
    Hernandez-Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM, et al. Role of thrombin in pulmonary fibrosis. Lancet 1995; 346: 10713.
  • 38
    Thuillier R, Favreau F, Celhay O, Macchi L, Milin S, Hauet T. Thrombin inhibition during kidney ischemia-reperfusion reduces chronic graft inflammation and tubular atrophy. Transplantation 2010; 90: 61221.
  • 39
    Favreau F, Thuillier R, Cau J, Milin S, Manguy E, Mauco G, et al. Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. Am J Transplant 2010; 10: 309.
  • 40
    Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L15260.
  • 41
    Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 111627.
  • 42
    Kim R, Meyer KC. Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2008; 2: 31938.
  • 43
    Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 147582.
  • 44
    Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 18859.